Equities research analysts expect Scholar Rock Holding Corp (NASDAQ:SRRK) to post ($0.74) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Scholar Rock’s earnings, with the highest EPS estimate coming in at ($0.44) and the lowest estimate coming in at ($1.17). The business is scheduled to report its next earnings report on Wednesday, November 14th.
On average, analysts expect that Scholar Rock will report full-year earnings of ($4.50) per share for the current fiscal year, with EPS estimates ranging from ($5.79) to ($2.95). For the next year, analysts expect that the company will post earnings of ($3.20) per share, with EPS estimates ranging from ($4.80) to ($2.27). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Scholar Rock.
Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($1.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.85).
A number of large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. acquired a new stake in Scholar Rock during the second quarter worth approximately $151,000. TD Asset Management Inc. acquired a new stake in Scholar Rock during the second quarter worth approximately $183,000. Quantitative Systematic Strategies LLC acquired a new stake in Scholar Rock during the second quarter worth approximately $193,000. Laurion Capital Management LP acquired a new stake in Scholar Rock during the second quarter worth approximately $234,000. Finally, Dean Capital Investments Management LLC acquired a new stake in Scholar Rock during the second quarter worth approximately $604,000. 48.37% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ SRRK traded down $1.31 during midday trading on Thursday, hitting $24.94. The company’s stock had a trading volume of 80,366 shares, compared to its average volume of 51,092. Scholar Rock has a 1 year low of $13.09 and a 1 year high of $27.02.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy.
Recommended Story: Hedge Funds Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.